OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 01:21:11 29/06/2024 am IST | ||
| 20.85 EUR | -1.18% |
|
| Current month | +9.74% | ||
| 1 month | +11.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 20.85 | -1.18% |
| 27/24/27 | 21.1 | +0.05% |
| 26/24/26 | 21.09 | -1.36% |
| 25/24/25 | 21.38 | +3.48% |
| 24/24/24 | 20.66 | -0.14% |
Delayed Quote Deutsche Boerse AG
Last update June 29, 2024 at 01:21 am IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SB8JM6 |
| ISIN | DE000SB8JM69 |
| Date issued | 07/08/2020 |
| Strike | 217.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.73 € |
|---|---|
| Lowest since issue | 0.26 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
